BTL Industries v. Beauty By Izzy — Default Judgment on Electromagnetic Body Contouring Patent
BTL Industries, Inc. secured a default judgment and permanent injunction against Beauty By Izzy and operator Isabel Gomez after 207 days, covering both Patent No. 10,478,634 on magnetic field aesthetic treatment and the EMSCULPT NEO trademark. The defendant never appeared, resulting in judgment on all four causes of action.
BTL’s EMSCULPT NEO patent enforced via default judgment in C.D. Cal.
BTL Industries, Inc., the developer and patent holder behind the EMSCULPT NEO body contouring system, filed suit on 9 June 2023 in the Central District of California against Beauty By Izzy and individual operator Isabel Gomez. The complaint alleged infringement of US Patent No. 10,478,634, which covers an aesthetic method of biological structure treatment by magnetic field, alongside trademark infringement of the EMSCULPT NEO mark under federal and common law, and federal unfair competition claims.
With no appearance or response from either defendant, BTL moved for default judgment. The court entered judgment on 2 January 2024 on all four causes of action, awarding BTL a permanent injunction prohibiting Gomez, her agents, employees, and anyone acting in concert from further infringement of both the EMSCULPT NEO trademark and Patent No. 10,478,634. The case closed 207 days after filing via default — a standard procedural outcome when defendants fail to respond.
The 207-day duration is consistent with default judgment timelines in the Central District, where default is typically entered within a few months of a defendant’s non-response. What remains unknown from the public record is whether any damages beyond injunctive relief were quantified or awarded, and whether BTL has pursued or intends to pursue collection. The case is one of several signals that BTL is actively enforcing its EMSCULPT NEO IP portfolio against small aesthetic service providers.
Filing to settlement in 207 days
207 days from filing to closed default judgment
Default judgment and permanent injunction entered on all four causes of action
What a default judgment means in patent litigation
A default judgment is entered when a defendant fails to appear or respond within the required timeframe. The court does not adjudicate the merits through adversarial proceedings — instead, well-pleaded factual allegations are treated as admitted. Here, Gomez’s non-appearance meant BTL’s claims on patent infringement, trademark infringement, and unfair competition were accepted without contest, resulting in judgment on all counts.
No merits adjudicationPermanent injunction covers patent and all EMSCULPT NEO trademarks
The court’s permanent injunction explicitly binds Gomez, her officers, agents, employees, and anyone acting in concert. It bars infringement of all BTL trademarks — specifically naming EMSCULPT NEO — and all BTL patents, specifically naming US10478634B2. This broad drafting suggests BTL sought maximum forward-looking protection, extending liability to associates or successor operators who might continue the same activity.
Broad forward-looking barCombined patent and trademark assertion is a deliberate enforcement strategy
BTL pursued four causes of action simultaneously: patent infringement, federal trademark infringement (§ 1114), federal unfair competition and false designation (§ 1125), and common law trademark infringement. Stacking these claims against a small beauty operator is consistent with a portfolio-wide enforcement approach, maximising remedies and deterrence across both the technical and brand layers of the EMSCULPT NEO product ecosystem.
Multi-claim enforcementSmall operator targeted — typical of downstream IP enforcement campaigns
Beauty By Izzy and Isabel Gomez represent the downstream end of the aesthetic device market — service providers rather than manufacturers. BTL’s decision to litigate to default judgment against a small operator, rather than settle quietly, is consistent with a deterrence-focused enforcement pattern intended to signal to the broader market of unauthorised users that BTL will pursue infringers regardless of scale.
Deterrence-focusedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | BTL Industries, Inc. | Company | Medical aesthetics device manufacturer — holder of US10478634B2 and EMSCULPT NEO trademarkSearch in Eureka ↗ |
| Defendant | Beauty By Izzy | Company | Beauty By Izzy, a small aesthetic services operator, and individual operator Isabel GomezSearch in Eureka ↗ |
| Plaintiff counsel | Randy R. Haj | Attorney | Counsel for BTL Industries, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Scott O. Luskin | Attorney | Counsel for BTL Industries, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Seth R. Ogden | Attorney | Counsel for BTL Industries, Inc.Search in Eureka ↗ |
| Presiding judge | Judge / | Chief Judge | California Central District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The court’s default judgment order enters liability on all four causes of action without contested merits proceedings — BTL’s pleaded allegations were taken as admitted. The permanent injunction is notably broad: it binds not just Gomez personally but all agents and persons acting in concert, which may extend to any future operator of the same business. The explicit naming of both the EMSCULPT NEO trademark and Patent No. 10,478,634 in the injunction text gives BTL a ready-made enforcement instrument against any continuation of the infringing activity.
US10478634B2 — Aesthetic Method of Biological Structure Treatment by Magnetic Field
US Patent No. 10,478,634 (application No. US16/034793) covers an aesthetic method of treating biological structures using a magnetic field — the core technical principle underlying BTL’s EMSCULPT NEO platform. The patent addresses a non-invasive approach to muscle stimulation and tissue remodelling via electromagnetic energy, a technically differentiated modality in the crowded non-surgical body contouring market. The application filing trajectory suggests BTL built IP protection around its clinical methodology, not just device hardware.
For competitors and adjacent technology developers, US10478634B2 represents a meaningful barrier in the electromagnetic aesthetic treatment space. Any service or device that uses magnetic field stimulation for biological tissue treatment — whether for muscle toning, fat reduction, or related indications — should be evaluated against the claims of this patent. BTL’s willingness to enforce against small operators signals that the patent is considered core IP, not a defensive filing, and that licensing is likely required for any commercial use.
Should your aesthetic device or service run an FTO against US10478634B2?
Any company developing, distributing, or operating devices that treat biological structures using magnetic field stimulation should treat US10478634B2 as a mandatory FTO checkpoint. This applies equally to device manufacturers entering the body contouring space, equipment distributors supplying aesthetic clinics, and clinic operators considering treatment modalities that overlap with electromagnetic muscle stimulation — the category at the heart of the EMSCULPT NEO platform.
PatSnap Eureka’s FTO Search Agent can map your device’s technical approach against the claims of US10478634B2 and identify related patents in BTL’s portfolio that may present adjacent risk. Continuous claim monitoring through Eureka also flags any continuations or divisionals filed from the same family — critical intelligence when a patent holder is demonstrably active in litigation enforcement.
Run a freedom-to-operate analysis on US10478634B2 to assess your product’s exposure
Run FTO in Eureka →Similar patent infringement cases in the aesthetic device and electromagnetic treatment sector
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the aesthetic device IP landscape
BTL’s default judgment reinforces active patent and trademark enforcement across the EMSCULPT NEO ecosystem, including against small service providers.
BTL is enforcing IP downstream — small operators are not safe
This case confirms BTL Industries pursues infringement at the service-provider level, not just against manufacturers or distributors. Aesthetic clinic operators using EMSCULPT NEO devices without authorisation — or marketing services under that brand without a license — face real litigation risk. The permanent injunction extends to anyone acting in concert with the named defendant.
Multi-layered IP enforcement raises the cost of infringement
By combining patent and trademark causes of action, BTL can pursue injunctive relief, potential damages, and brand protection in a single proceeding. Companies in the aesthetic device sector should audit both their device sourcing and their marketing language — unauthorised use of protected technology names can trigger trademark exposure independently of any patent question.
BTL v Beauty — key questions answered
BTL Industries obtained a default judgment against Beauty By Izzy and Isabel Gomez on 2 January 2024. The court entered judgment on all four causes of action — patent infringement of US10478634B2, federal trademark infringement, federal unfair competition, and common law trademark infringement — and issued a permanent injunction barring further infringement.
US Patent No. 10,478,634 covers an aesthetic method of biological structure treatment by magnetic field. It underpins the EMSCULPT NEO platform, protecting BTL’s clinical methodology for using electromagnetic energy to treat muscle and biological tissue non-invasively. The patent is asserted as core IP in BTL’s enforcement strategy.
A default judgment was entered because the defendants — Beauty By Izzy and Isabel Gomez — failed to appear or respond to the complaint after being served. Under Federal Rules of Civil Procedure, a court may enter default judgment when a defendant does not respond, treating the plaintiff’s well-pleaded allegations as admitted without adversarial merits proceedings.
The permanent injunction prohibits Gomez, her officers, agents, employees, and all persons acting in concert from further infringement of BTL’s trademarks — specifically naming EMSCULPT NEO — and BTL’s patents, specifically naming US10478634B2. The broad drafting extends the bar beyond Gomez personally to anyone associated with the infringing activity.
This case suggests BTL actively enforces US10478634B2 across the market, including against small service providers. While a default judgment does not constitute a judicial finding on patent validity or claim scope through contested proceedings, it signals that BTL treats this patent as enforceable core IP. Aesthetic device manufacturers and clinic operators should assess FTO exposure against this patent’s claims.
PatSnap Eureka searches patents and litigation data to answer instantly.